(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) fell by a staggering 34.02% in 21 sessions from €0.14 to €0.09 at 05:12 EST on Wednesday, following the last session’s upward trend. BEL 20 is falling 1.09% to €3,760.41, following the last session’s downward trend.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.29.
Volatility
BIOSENIC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.01%, a negative 2.97%, and a positive 5.94%.
BIOSENIC’s highest amplitude of average volatility was 6.35% (last week), 3.96% (last month), and 5.94% (last quarter).
Volume
Today’s last reported volume for BIOSENIC is 205193 which is 51.66% below its average volume of 323400.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC’s stock is considered to be oversold (<=20).
More news about BIOSENIC (BIOS.BR).
